These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

473 related articles for article (PubMed ID: 26593250)

  • 21. Molecular chaperone GRP78 enhances aggresome delivery to autophagosomes to promote drug resistance in multiple myeloma.
    Abdel Malek MA; Jagannathan S; Malek E; Sayed DM; Elgammal SA; Abd El-Azeem HG; Thabet NM; Driscoll JJ
    Oncotarget; 2015 Feb; 6(5):3098-110. PubMed ID: 25605012
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mechanistic rationale for targeting the unfolded protein response in pre-B acute lymphoblastic leukemia.
    Kharabi Masouleh B; Geng H; Hurtz C; Chan LN; Logan AC; Chang MS; Huang C; Swaminathan S; Sun H; Paietta E; Melnick AM; Koeffler P; Müschen M
    Proc Natl Acad Sci U S A; 2014 May; 111(21):E2219-28. PubMed ID: 24821775
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of casein kinase 2 modulates XBP1-GRP78 arm of unfolded protein responses in cultured glial cells.
    Hosoi T; Korematsu K; Horie N; Suezawa T; Okuma Y; Nomura Y; Ozawa K
    PLoS One; 2012; 7(6):e40144. PubMed ID: 22768244
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The NEDD8-activating enzyme inhibitor pevonedistat activates the eIF2α and mTOR pathways inducing UPR-mediated cell death in acute lymphoblastic leukemia.
    Leclerc GM; Zheng S; Leclerc GJ; DeSalvo J; Swords RT; Barredo JC
    Leuk Res; 2016 Nov; 50():1-10. PubMed ID: 27626202
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Protein kinase CK2 is widely expressed in follicular, Burkitt and diffuse large B-cell lymphomas and propels malignant B-cell growth.
    Pizzi M; Piazza F; Agostinelli C; Fuligni F; Benvenuti P; Mandato E; Casellato A; Rugge M; Semenzato G; Pileri SA
    Oncotarget; 2015 Mar; 6(9):6544-52. PubMed ID: 25788269
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mechanism of the induction of endoplasmic reticulum stress by the anti-cancer agent, di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT): Activation of PERK/eIF2α, IRE1α, ATF6 and calmodulin kinase.
    Merlot AM; Shafie NH; Yu Y; Richardson V; Jansson PJ; Sahni S; Lane DJR; Kovacevic Z; Kalinowski DS; Richardson DR
    Biochem Pharmacol; 2016 Jun; 109():27-47. PubMed ID: 27059255
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CX-4945, a Selective Inhibitor of Casein Kinase 2, Synergizes with B Cell Receptor Signaling Inhibitors in Inducing Diffuse Large B Cell Lymphoma Cell Death.
    Mandato E; Nunes SC; Zaffino F; Casellato A; Macaccaro P; Tubi LQ; Visentin A; Trentin L; Semenzato G; Piazza F
    Curr Cancer Drug Targets; 2018; 18(6):608-616. PubMed ID: 28460620
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bortezomib Treatment can Overcome Glucocorticoid Resistance in Childhood B-cell Precursor Acute Lymphoblastic Leukemia Cell Lines.
    Junk S; Cario G; Wittner N; Stanulla M; Scherer R; Schlegelberger B; Schrappe M; von Neuhoff N; Lauten M
    Klin Padiatr; 2015 May; 227(3):123-30. PubMed ID: 25985447
    [TBL] [Abstract][Full Text] [Related]  

  • 29. IKAROS and CK2 regulate expression of BCL-XL and chemosensitivity in high-risk B-cell acute lymphoblastic leukemia.
    Song C; Ge Z; Ding Y; Tan BH; Desai D; Gowda K; Amin S; Gowda R; Robertson GP; Yue F; Huang S; Spiegelman V; Payne JL; Reeves ME; Gurel Z; Iyer S; Dhanyamraju PK; Xiang M; Kawasawa YI; Cury NM; Yunes JA; McGrath M; Schramm J; Su R; Yang Y; Zhao Z; Lyu X; Muschen M; Payne KJ; Gowda C; Dovat S
    Blood; 2020 Sep; 136(13):1520-1534. PubMed ID: 32396934
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Endoplasmic reticulum stress, unfolded protein response and autophagy contribute to resistance to glucocorticoid treatment in human acute lymphoblastic leukaemia cells.
    Sudsaward S; Khunchai S; Thepmalee C; Othman A; Limjindaporn T; Yenchitsomanus PT; Mutti L; Krstic-Demonacos M; Demonacos C
    Int J Oncol; 2020 Sep; 57(3):835-844. PubMed ID: 32705154
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Unfolded Protein Response: A Novel Therapeutic Target for Poor Prognostic
    Forsythe N; Refaat A; Javadi A; Khawaja H; Weir JA; Emam H; Allen WL; Burkamp F; Popovici V; Jithesh PV; Isella C; Labonte MJ; Mills IG; Johnston PG; Van Schaeybroeck S
    Mol Cancer Ther; 2018 Jun; 17(6):1280-1290. PubMed ID: 29483217
    [No Abstract]   [Full Text] [Related]  

  • 32. AAV delivery of GRP78/BiP promotes adaptation of human RPE cell to ER stress.
    Ghaderi S; Ahmadian S; Soheili ZS; Ahmadieh H; Samiei S; Kheitan S; Pirmardan ER
    J Cell Biochem; 2018 Feb; 119(2):1355-1367. PubMed ID: 28782832
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CK2 inhibitor CX-4945 destabilizes NOTCH1 and synergizes with JQ1 against human T-acute lymphoblastic leukemic cells.
    Lian H; Li D; Zhou Y; Landesman-Bollag E; Zhang G; Anderson NM; Tang KC; Roderick JE; Kelliher MA; Seldin DC; Fu H; Feng H
    Haematologica; 2017 Jan; 102(1):e17-e21. PubMed ID: 27758824
    [No Abstract]   [Full Text] [Related]  

  • 34. Valosin-Containing Protein/p97 as a Novel Therapeutic Target in Acute Lymphoblastic Leukemia.
    Gugliotta G; Sudo M; Cao Q; Lin DC; Sun H; Takao S; Le Moigne R; Rolfe M; Gery S; Müschen M; Cavo M; Koeffler HP
    Neoplasia; 2017 Oct; 19(10):750-761. PubMed ID: 28843399
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ER stress signaling in ARPE-19 cells after inhibition of protein kinase CK2 by CX-4945.
    Intemann J; Saidu NE; Schwind L; Montenarh M
    Cell Signal; 2014 Jul; 26(7):1567-75. PubMed ID: 24686080
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sphingosine kinase 2 inhibition synergises with bortezomib to target myeloma by enhancing endoplasmic reticulum stress.
    Wallington-Beddoe CT; Bennett MK; Vandyke K; Davies L; Zebol JR; Moretti PAB; Pitman MR; Hewett DR; Zannettino ACW; Pitson SM
    Oncotarget; 2017 Jul; 8(27):43602-43616. PubMed ID: 28467788
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination of bortezomib and daunorubicin in the induction of apoptosis in T-cell acute lymphoblastic leukemia.
    Du X; Tong J; Lu H; He C; Du S; Jia P; Zhao W; Xu H; Li J; Shen Z; Wu Y; Tong J; Zhou L
    Mol Med Rep; 2017 Jul; 16(1):101-108. PubMed ID: 28487980
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Smac mimetic LCL161 overcomes protective ER stress induced by obatoclax, synergistically causing cell death in multiple myeloma.
    Ramakrishnan V; Gomez M; Prasad V; Kimlinger T; Painuly U; Mukhopadhyay B; Haug J; Bi L; Rajkumar SV; Kumar S
    Oncotarget; 2016 Aug; 7(35):56253-56265. PubMed ID: 27494845
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Requirement of apoptotic protease-activating factor-1 for bortezomib-induced apoptosis but not for Fas-mediated apoptosis in human leukemic cells.
    Ottosson-Wadlund A; Ceder R; Preta G; Pokrovskaja K; Grafström RC; Heyman M; Söderhäll S; Grandér D; Hedenfalk I; Robertson JD; Fadeel B
    Mol Pharmacol; 2013 Jan; 83(1):245-55. PubMed ID: 23093495
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells.
    Obeng EA; Carlson LM; Gutman DM; Harrington WJ; Lee KP; Boise LH
    Blood; 2006 Jun; 107(12):4907-16. PubMed ID: 16507771
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.